Edwards Lifesciences (NYSE:EW) Removed From Multiple Russell Growth Indexes

Edwards Lifesciences (NYSE:EW) experienced a 7.91% price increase over the last quarter, amidst significant developments. On June 30, 2025, the company was removed from several Russell indices, potentially affecting its visibility among growth-focused funds and possibly influencing institutional investment. However, Edwards Lifesciences bolstered its market position with key product approvals, including Health Canada's approval of its EVOQUE tricuspid valve replacement system and the FDA's approval of the SAPIEN 3 TAVR therapy for asymptomatic patients. These approvals may have bolstered investor confidence, even as broader indices like the S&P 500 and Nasdaq reached new highs, reflecting positive market sentiment.

Buy, Hold or Sell Edwards Lifesciences? View our complete analysis and fair value estimate and you decide.

AI is about to change healthcare. These 25 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

The recent approvals for Edwards Lifesciences, notably from Health Canada for its EVOQUE tricuspid valve replacement system and the FDA for its SAPIEN 3 TAVR therapy, have the potential to significantly impact revenue and earnings forecasts. These milestones may increase product adoption and market penetration, supporting longer-term revenue targets projected by analysts. However, the removal from several Russell indices could challenge its visibility among growth-focused investors, impacting institutional demand and potentially limiting the upside witnessed in the recent quarter.

Over the past five years, Edwards Lifesciences' total return, combining share price appreciation and dividends, was 13.04%. This performance is notable against a one-year backdrop where the company underperformed the US Medical Equipment industry, which saw a 9.5% return. This underperformance puts into perspective the current share price movement and analyst expectations regarding future growth.

Despite the current share price increase, Edwards' shares are trading below the consensus analyst price target of US$81.01, reflecting a cautious optimism among analysts. While the price target reflects potential growth prospects, it indicates that current market expectations are relatively aligned with these projections, allowing room for investors to evaluate future performance against these benchmarks. The impact of the recent news may thus be pivotal in determining whether Edwards can achieve the expected earnings growth and valuations, especially given anticipated revenue increases and market challenges.

Take a closer look at Edwards Lifesciences' potential here in our financial health report.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com